Specifications table {#s0005}
====================

TableSubject area*Biology*More specific subject area*Clinical Proteomics*Type of data1.*RAW MS Orbitrap XL data*2.*MaxQuant "Protein groups.txt" output*How data was acquired*LTQ Orbitrap XL MS interfaced with a reverse phase column (PepMap C18, 75* *µm ID x 50* *cm, 3* *µm particle size, 100* *Å pore size).*Data format*RAW;.txt*Experimental factors*All ER positive fresh frozen breast cancer tissues were subjected to LCM to enrich for epithelial tumor cells prior to protein digestion, which enabled analysis of highly pure subpopulations of breast cancer cells.*Experimental features1.*Cryo-sectioning of breast cancer tissues and collection on polyethylene--naphtalate coated slides*2.*Hematoxylin staining and LCM-enrichment*3.*Protein digestion (MS Grade Trypsin)*4.*LC--MS analysis*5.*Label-free quantitation (LFQ) by MaxQuant software*Data source location*Rotterdam, The Netherlands*Data accessibility*PXD000484:*<http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD000484>*PXD000485:*<http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD000485>

Value of the data {#s0010}
=================

•First public proteomics datasets of LCM derived ER positive primary tumor cells analyzed by high resolution MS.•Characterization of proteomic changes related to resistance to first line tamoxifen therapy.•Quantification of 3109 and 4061 unique proteins in training and test sets, respectively.

1. Materials and methods {#s0015}
========================

1.1. Sample sets {#s0020}
----------------

We collected a total of 112 fresh frozen ER positive breast cancer tissues that displayed a minimum ( ≥) of 40% tumor area and that were collected from patients who received tamoxifen therapy for recurrent disease and no adjuvant hormonal therapy after resection of the primary tumor. Patient groups were defined based on outcome to tamoxifen therapy for recurrent disease: patients who manifested progression of disease within (≤) 6 months after start of therapy were defined as manifesting poor outcome, while the good outcome group comprised patients with disease progression after (\>) 6 months. Patient samples in the training set (PXD000484) were collected from Erasmus Medical Center (*n*=56; 32×good, 24×poor), while the test set (PXD000485) comprised tumors collected from the Netherlands Cancer Institute -- Antoni van Leeuwenhoek hospital (*n*=41) and Radboud University Medical Center (*n*=15), which comprised 41 good and 15 poor outcome patients, respectively, as previously reported (Ref. [@bib2]). Clinical information for every patient in the training an test sets are reported in [Tables S1](#s0055){ref-type="sec"} and [S2](#s0055){ref-type="sec"}, respectively.

1.2. Sample preparation {#s0025}
-----------------------

Breast cancer tissue samples were processed according to our previously reported tissue proteomic workflow [@bib4], [@bib5]. Frozen tissue specimens were cut into 8 µm cryo-sections, collected on polyethylene naphtalate coated glass slides, and stained with hematoxylin. From each sample, around 4000 epithelial tumor cells were collected through LCM (corresponding to an area of \~500,000 µm^2^) and suspended into 20 µl of 0.1% w/v Rapigest/50 mM ammonium bicarbonate solution.

1.3. Protein digestion {#s0030}
----------------------

LCM collected tissues were lysed through sonication at 70% amplitude. Proteins were denatured at 95 °C, reduced with a 100 µM dithiothreithol solution, and alkylated with a 300 mM iodoacetamide solution. MS grade trypsin was added in a 1:4 enzyme--protein ratio and incubated for 4 h at 37 °C. Digested samples were then acidified with trifluoroacetic acid and spun down at 14,000 RPM. Supernatants were collected and transferred to HPLC vials for further MS measurement.

1.4. High resolution MS analysis {#s0035}
--------------------------------

MS measurements were performed as previously described with on an LTQ Orbitrap XL interfaced with a nano liquid chromatography system (Ultimate 3000, Dionex, Amsterdam, The Netherlands) [@bib2], [@bib5], [@bib6]. Digested proteins were separated on a reverse phase analytical column (PepMap C18, 75 μm ID×50 cm, 3 μm particle size and 100 Å pore size) in a 3 h gradient: 2 h 0--25% mobile phase B (80% acetonitrile and 0.08% formic acid), and 1 h 25--50% mobile phases B and A (2% acetonitrile and 0.1% formic acid in purified water). The top 5 most intense peaks in full scan (from 400 to 1800 Th) were fragmented by collision induced dissociation.

1.5. Protein identification and quantitation {#s0040}
--------------------------------------------

Orbitrap.RAW files were analyzed by MaxQuant (v1.2.2.5), using Andromeda for peptide search [@bib3], [@bib7]. UniProt-SwissProt human canonical database (version 2012-09, human canonical proteome; 20,243 identifiers) was used as reference database. For identification, peptide length was set to 7 aminoacids, match between runs was enabled and settings were kept as default. All other settings were set as default. "Protein groups.txt" files were uploaded in ProteomeXchange along with Orbitrap.RAW files.
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Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.dib.2015.09.034](http://dx.doi.org/10.1016/j.dib.2015.09.034){#ir0015}.

[^1]: Current address: Department of Molecular Biology, Radboud University Nijmegen, Faculty of Science, Radboud Institute for Molecular Life Sciences, The Netherlands.
